STOCK TITAN
  1. Home
  2. News
  3. BCRX

Biocryst Pharmaceuticals Inc Stock Price, News & Analysis

BCRX Nasdaq

Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.

BioCryst Pharmaceuticals Inc (BCRX) is a biotechnology leader developing innovative therapies for rare diseases and infectious conditions through targeted enzyme inhibition. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives.

Access authoritative reporting on BCRX's pipeline progress, including updates on hereditary angioedema treatments and antiviral therapies. Our curated collection features earnings announcements, research breakthroughs, and partnership disclosures – all essential for tracking this biopharma innovator.

Key updates include FDA decisions, clinical trial results, and scientific publications. Bookmark this page for streamlined access to verified BioCryst news, eliminating the need to monitor multiple sources. Check regularly for developments impacting the company's position in enzyme inhibitor therapeutics and rare disease treatment markets.

News

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

Rhea-AI Summary
BioCryst Pharmaceuticals presented new data demonstrating the long-term efficacy and safety of ORLADEYO (berotralstat) for hereditary angioedema (HAE) treatment across all age groups at EAACI 2025. Key findings from four studies showed: (1) In pediatric patients, an 86% reduction in attacks requiring professional care was observed after 12 weeks of treatment. (2) The Berolife study showed sustained attack reduction in patients aged >12 years, with median monthly attacks decreasing from 1.0 to 0.44 after six months. (3) Quality of life studies revealed significant improvements in patient outcomes, with 60% achieving Minimal Clinically Important Difference at week 24. (4) Focus group results indicated positive patient experiences, including better disease control and easier treatment management compared to previous therapies. The drug demonstrated consistent safety across all studies, with common side effects including nasopharyngitis and headache.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
-
News

ORLADEYO® (berotralstat) Approved in Colombia

Rhea-AI Summary
BioCryst Pharmaceuticals (BCRX) has received approval from Colombia's National Institute of Drug and Food Surveillance (INVIMA) for ORLADEYO (berotralstat), an oral, once-daily treatment for hereditary angioedema (HAE) attack prevention in patients aged 12 and older. This approval expands ORLADEYO's presence in the pan-Latin America region, where it's already approved in Chile, Argentina, Brazil, Mexico, and Peru. BioCryst's partnership with Pint Pharma GmbH involves exclusive collaboration for registration and promotion in the region, with Pint handling marketing authorizations and commercialization responsibilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
-
News

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

Rhea-AI Summary
BioCryst Pharmaceuticals announced that ORLADEYO (berotralstat) has received reimbursement approval in the Netherlands for preventing hereditary angioedema (HAE) attacks in patients 12 years and older. This milestone completes ORLADEYO's reimbursement coverage across all major European countries, marking significant progress for the first oral, once-daily preventive therapy for HAE. The approval follows a positive recommendation from Zorginstituut Nederland and builds upon the European Commission's marketing authorization granted in April 2021. ORLADEYO is now commercially available in over 30 countries, representing a major advancement in HAE treatment accessibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
News

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
BioCryst Pharmaceuticals (BCRX) has granted restricted stock units (RSUs) to seven newly-hired employees as employment inducements. The compensation committee approved RSUs covering 47,250 shares of BioCryst common stock, effective June 2, 2025. These equity awards, granted under Nasdaq Listing Rule 5635(c)(4), will vest over four years in equal annual installments, starting from the one-year anniversary of the grant date. The vesting is contingent upon continued employment with BioCryst. The RSUs are governed by BioCryst's Inducement Equity Incentive Plan and individual RSU agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
none
-
News

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

Rhea-AI Summary
BioCryst Pharmaceuticals (BCRX) announced it will present new data on ORLADEYO (berotralstat), its oral once-daily treatment for hereditary angioedema (HAE), at the 2025 EAACI meeting in Glasgow. The company will showcase four abstracts highlighting different aspects of ORLADEYO's effectiveness: a pooled analysis of quality of life data from APeX-2 and APeX-J trials, patient perceptions from focus groups, long-term prophylaxis findings from the Berolife study, and interim results from APeX-P showing reduced HAE attacks in pediatric patients. The presentations are scheduled for June 14-15, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
conferences
-
News

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

Rhea-AI Summary
BioCryst Pharmaceuticals presented new data at the 14th C1-inhibitor Deficiency & Angioedema Workshop demonstrating ORLADEYO's (berotralstat) effectiveness in reducing hereditary angioedema (HAE) attacks across all age groups. The APeX-P trial showed significant symptom reduction in young children, with angioedema symptoms decreasing from 11% to 4% over 12 weeks. The Italian expanded access program revealed improved disease control and quality of life scores, while the Berolife study demonstrated sustained attack rate reduction in adolescents from 1.8 to 0.55 attacks per month. The drug showed consistent safety profiles across all age groups, with common side effects including nasopharyngitis, upper respiratory tract infection, and headache. The data supports ORLADEYO as an effective oral, once-daily prophylactic treatment option for HAE patients of all ages.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
none
News

BioCryst to Present at Upcoming Investor Conferences

Rhea-AI Summary

BioCryst Pharmaceuticals (NASDAQ: BCRX) has announced its participation in two major upcoming investor conferences. The company will present at the Jefferies Global Healthcare Conference in New York on June 4, 2025, at 4:55 p.m. ET, and at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 9, 2025, at 8:40 a.m. ET. Investors can access live audio webcasts and replays of both presentations through the Investors & Media section of BioCryst's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
conferences
-
News

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

Rhea-AI Summary
BioCryst Pharmaceuticals (BCRX) presented new real-world evidence demonstrating the effectiveness of ORLADEYO® (berotralstat) in treating Hereditary Angioedema (HAE) at ISPOR 2025. The study analyzed data from December 2020 to January 2024, focusing on two patient groups: 1. Severe HAE Patients (56 patients): - Baseline: 7.78-8.23 attacks/month - After ORLADEYO: 1.24-1.90 attacks/month - At 18 months: 6.43 fewer attacks/month 2. Adolescent Patients (99 patients aged 12-17): - Baseline: 2.07-2.30 attacks/month - After ORLADEYO: 0.36-0.76 attacks/month - At 18 months: 1.85 fewer attacks/month The results demonstrate significant and sustained reductions in HAE attack rates through 18 months of treatment, showing ORLADEYO's effectiveness across different patient populations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
News

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

Rhea-AI Summary

The FDA has accepted BioCryst Pharmaceuticals' (BCRX) New Drug Application for ORLADEYO® oral granules to treat hereditary angioedema (HAE) in children aged 2-11 years. The FDA granted Priority Review with a PDUFA target date of September 12, 2025.

The application is based on positive interim data from the APeX-P clinical trial, showing ORLADEYO was well-tolerated with sustained reductions in monthly attack rates. The trial revealed HAE symptoms typically onset at age two, indicating a significant early disease burden. If approved, ORLADEYO would become the first targeted oral prophylactic therapy for HAE patients under 12 years old.

BioCryst has also filed for approval in Europe, with plans for additional submissions in Japan and Canada. ORLADEYO is currently approved for patients 12 years and older in over 30 countries since December 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
clinical trial fda approval
News

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

Rhea-AI Summary
BioCryst Pharmaceuticals reported strong Q1 2025 financial results, with ORLADEYO net revenue reaching $134.2 million, a 51% year-over-year increase. The company raised its full-year 2025 ORLADEYO revenue guidance to $580-600 million, up from $535-550 million. Total revenues were $145.5 million, up 56.8% year-over-year. BioCryst achieved profitability ahead of schedule, now expecting net income and positive cash flows for full year 2025. The company paid down $75 million in debt, saving approximately $23.5 million over the loan's life. Key developments include an NDA submission for ORLADEYO oral granules for children with HAE aged 2-11, and FDA clearance of the IND for BCX17725 for Netherton syndrome. The percentage of ORLADEYO patients on paid drug increased to 84%, and U.S. HAE patients showing strong preference for oral prophylaxis therapy rose to 70%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.52%
Tags
earnings

FAQ

What is the current stock price of Biocryst Pharmaceuticals (BCRX)?

The current stock price of Biocryst Pharmaceuticals (BCRX) is $9.97 as of June 17, 2025.

What is the market cap of Biocryst Pharmaceuticals (BCRX)?

The market cap of Biocryst Pharmaceuticals (BCRX) is approximately 2.3B.
Stock BCRX logo
Biocryst Pharmaceuticals Inc

Nasdaq:BCRX

BCRX Rankings

#1853 Ranked by Market Cap
N/A Ranked by Dividends

BCRX Stock Data

2.32B
202.90M
1.44%
81.14%
7.66%
Drug Manufacturers - Specialty & Generic
Biological Products, (no Disgnostic Substances)
Link
United States
DURHAM